Mineralys Therapeutics (MLYS) Cash & Equivalents (2022 - 2026)
Mineralys Therapeutics (MLYS) posted Cash & Equivalents of $111.6 million for Q1 2026, down 35.45% sequentially from $172.9 million in Q4 2025, and down 32.35% YoY from $165.0 million in Q1 2025.
Mineralys Therapeutics (MLYS) Cash & Equivalents (2022 - 2026) Analysis & Trends
Mineralys Therapeutics has reported Cash & Equivalents for 5 years, with the latest figure at $111.6 million in Q1 2026.
- Quarterly Cash & Equivalents fell 32.35% year-over-year to $111.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $111.6 million (down 32.35% YoY) and the FY2025 annual result came in at $172.9 million, up 51.56% from the prior year.
- Cash & Equivalents eased to $111.6 million in Q1 2026 per MLYS's latest filing, from $172.9 million in the prior quarter.
- Over five years, Cash & Equivalents peaked at $217.6 million in Q3 2025 and troughed at $49.3 million in Q4 2023.
- A 5-year average of $113.4 million and a median of $99.0 million in 2024 frame the typical range for Cash & Equivalents.
- The sharpest annual moves came in 2023 and 2024: Cash & Equivalents slumped 43.78% in 2023, then soared 131.4% in 2024.
- Over 5 years, Cash & Equivalents stood at $87.7 million in 2022, then plunged by 43.78% to $49.3 million in 2023, then jumped by 131.4% to $114.1 million in 2024, then jumped by 51.56% to $172.9 million in 2025, then plunged by 35.45% to $111.6 million in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $111.6 million, $172.9 million, and $217.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.14 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.46 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 3.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 815.44 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.37 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 811.99 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.71 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 544.80 Mn |
| 10 | Mineralys Therapeutics | 2.27 Bn | 1.60 Bn | - | 138.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 138.27 Mn |
| Mar 31, 2026 | 111.63 Mn |
| Dec 31, 2025 | 172.92 Mn |
| Sep 30, 2025 | 217.60 Mn |
| Jun 30, 2025 | 100.78 Mn |
| Mar 31, 2025 | 165.01 Mn |
| Dec 31, 2024 | 114.09 Mn |
| Sep 30, 2024 | 97.27 Mn |
| Jun 30, 2024 | 67.76 Mn |
| Mar 31, 2024 | 90.42 Mn |
| Dec 31, 2023 | 49.30 Mn |
| Sep 30, 2023 | 84.95 Mn |
| Jun 30, 2023 | 93.51 Mn |
| Mar 31, 2023 | 135.34 Mn |
| Dec 31, 2022 | 87.70 Mn |